がん遺伝子治療市場- 世界の産業規模、シェア、動向、機会、予測、治療別、適応症別、エンドユーザー別、地域別セグメント、競合、2020年～2030年

がん遺伝子治療の世界市場規模は、2024年に45億2,000万米ドルとなり、予測期間中のCAGRは20.12%で、2030年には135億8,000万米ドルに達すると予測されています。

がん遺伝子治療の世界市場は大きな成長を遂げており、その原動力となっているのは、低コストで痛みの少ない治療に対する需要の高まりと、人々の美意識の高まりが、世界各地でがん遺伝子治療の需要を大きく伸ばしていることです。また、遺伝子治療や診断の利点に関する認知度の高まりや、がん治療に対するヘルスケア支出の増加が、予測期間中のがん遺伝子治療市場をさらに下支えすると見られています。2022年には、米国で推定6万6,470人（男性4万8,520人、女性1万7,950人）が頭頸部がんと診断されます。がんは世界で最も死亡率の高い疾患の一つであり、数十年にわたって公衆衛生上の重大な関心事となっています。

市場促進要因

世界のがん罹患率の上昇と精密治療の必要性

主な市場課題

高コストと遺伝子治療へのアクセス制限

主要市場動向

個別化治療の拡大がん遺伝子治療

目次

第1章 概要

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 顧客の声

第5章 臨床試験分析

第6章 世界のがん遺伝子治療市場展望

• 市場規模・予測
  • 金額別
• 市場シェア・予測
  • 治療別（腫瘍溶解性ウイルス療法、遺伝子誘導免疫療法、遺伝子導入、その他）
  • 適応症別（乳がん、卵巣がん、肺がん、肝がん、膵臓がん、前立腺がん、その他）
  • エンドユーザー別（バイオテクノロジー・製薬企業、学術・調査機関、その他）
  • 地域別
  • 企業別（2024）
• 市場マップ

第7章 北米のがん遺伝子治療市場展望

• 市場規模・予測
• 市場シェア・予測
• 北米：国別分析
  • 米国
  • カナダ
  • メキシコ

第8章 欧州のがん遺伝子治療市場展望

• 市場規模・予測
• 市場シェア・予測
• 欧州：国別分析
  • フランス
  • ドイツ
  • 英国
  • イタリア
  • スペイン

第9章 アジア太平洋地域のがん遺伝子治療市場展望

• 市場規模・予測
• 市場シェア・予測
• アジア太平洋地域：国別分析
  • 中国
  • インド
  • 日本
  • 韓国
  • オーストラリア

第10章 南米のがん遺伝子治療市場展望

• 市場規模・予測
• 市場シェア・予測
• 南米：国別分析
  • ブラジル
  • アルゼンチン
  • コロンビア

第11章 中東・アフリカのがん遺伝子治療市場展望

• 市場規模・予測
• 市場シェア・予測
• 中東・アフリカ：国別分析
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦

第12章 市場力学

• 促進要因
• 課題

第13章 市場動向と発展

• 最近の動向
• 合併と買収
• 製品上市

第14章 競合情勢

• Abeona Therapeutics Inc.
• Asklepios BioPharmaceutical Inc.
• Altor Bioscience Inc.
• BioCancell Inc.
• Celgene Inc.
• Elevate Bio Inc.
• Genelux Corporation
• Introgen Therapeutics Inc.
• OncoGenex Pharmaceuticals Inc.
• Merck KGaA

第15章 戦略的提言

第16章 調査会社について・免責事項

Global Cancer Gene Therapy Market was valued at USD 4.52 billion in 2024 and is expected to reach USD 13.58 billion by 2030 with a CAGR of 20.12% during the forecast period. The global market for Cancer Gene Therapy is experiencing significant growth, driven by the growing demand for painless treatment at lower cost coupled with increasing aesthetic consciousness among the population significantly increase the demand for cancer gene therapy across different parts of the globe. Besides, growing awareness about advantages of using gene therapy and diagnosis along with increasing healthcare expenditure on cancer treatment across the globe is further expected to support the Cancer Gene Therapy Market during the forecast period. In 2022, an estimated 66,470 people (48,520 men and 17,950 women) will be diagnosed with head and neck cancer in the United States. Cancer is one of the deadliest diseases in the world, and it has been a significant concern for public health for decades.

Key Market Drivers

Rising Global Cancer Burden and Need for Precision Therapies

The rising global burden of cancer is a fundamental driver of the cancer gene therapy market. According to the World Health Organization (WHO), cancer is a leading cause of death globally, responsible for nearly 10 million deaths in 2020. The most common forms include lung, breast, colorectal, prostate, and stomach cancer. Traditional treatments like chemotherapy and radiation often have systemic toxicity and variable efficacy, particularly in advanced-stage or genetically complex tumors. Gene therapy offers a transformative approach to cancer treatment by directly targeting the genetic root of disease-whether through inserting therapeutic genes, editing faulty ones, or using viral vectors to trigger immune responses. This is especially critical in cancers where oncogenic mutations drive resistance to conventional therapies.

The U.S. National Cancer Institute (NCI) and similar institutions in Europe and Asia are significantly increasing funding for precision medicine and gene-based oncology research. In the U.S., the 21st Century Cures Act and initiatives like the Cancer Moonshot have allocated billions toward advanced cancer research, including gene therapy. As the prevalence of cancer continues to climb due to aging populations and environmental exposures, the demand for targeted and durable treatments like gene therapy is expected to rise. These therapies not only promise improved survival outcomes but also offer the potential for long-term remission or even cures, particularly in genetically defined cancers like hematological malignancies or glioblastomas.

Key Market Challenges

High Cost and Limited Access to Gene Therapy

One of the primary challenges facing the global cancer gene therapy market is the high cost of treatment and the resultant limited patient access, particularly in low- and middle-income countries. Gene therapy, especially when customized for individuals, requires sophisticated manufacturing processes, skilled personnel, and stringent regulatory compliance, all of which contribute to its premium price. Approved therapies like CAR-T treatments have been priced between $350,000 to $500,000 per patient in markets like the U.S. and Europe. This cost does not account for hospitalization, supportive care, or follow-up, making the overall financial burden even higher. These prices place a significant strain on healthcare systems, especially those that operate on public insurance or low reimbursement thresholds.

Government health agencies, including the U.S. Centers for Medicare & Medicaid Services (CMS), have explored reimbursement models like outcomes-based pricing to make these therapies more sustainable. However, in many parts of Asia, Africa, and Latin America, such policies are either underdeveloped or non-existent, preventing wider adoption of gene therapy innovations. The affordability issue becomes more complex when considering the need for lifelong monitoring and potential retreatment. As gene therapies are still in the early stage of commercialization, cost reduction through economies of scale has not yet materialized. Until these therapies become more economically viable and globally accessible, their impact on global cancer care will remain uneven.

Key Market Trends

Expansion of Personalized Cancer Gene Therapy

A major trend in the global cancer gene therapy market is the movement toward highly personalized medicine. Advances in genomics and next-generation sequencing (NGS) have enabled detailed characterization of cancer at the molecular level, identifying specific genetic mutations, epigenetic modifications, and biomarkers. This data is being used to tailor gene therapies uniquely suited to individual patients' tumor profiles. For instance, gene-editing platforms like CRISPR-Cas9 are now being explored to create bespoke cancer therapies, where genes are selectively silenced or corrected. Similarly, personalized CAR-T cell therapies-where a patient's T-cells are genetically modified to recognize tumor-specific antigens-have already shown success in treating refractory blood cancers like leukemia and lymphoma.

Global governments are actively investing in precision oncology. For example, the U.K. has launched the Genomic Medicine Service within the NHS, integrating whole genome sequencing into cancer diagnosis and treatment planning. In the United States, the Precision Medicine Initiative supports integrating molecular data into clinical care, including gene therapy applications. This trend signifies a shift from the "one-size-fits-all" treatment paradigm to customized interventions with potentially fewer side effects and higher therapeutic success. As genomic profiling becomes more accessible, the scope for personalized gene therapy will continue to expand, reshaping the way cancer is treated across various demographics and geographies.

Key Market Players

• Abeona Therapeutics Inc.
• Asklepios BioPharmaceutical Inc.
• Altor Bioscience Inc.
• BioCancell Inc.
• Celgene Inc.
• Elevate Bio Inc.
• Genelux Corporation
• Introgen Therapeutics Inc.
• OncoGenex Pharmaceuticals Inc.
• Merck KGaA

Report Scope:

In this report, the Global Cancer Gene Therapy Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Cancer Gene Therapy Market, By Therapy:

• Oncolytic Virotherapy
• Gene Induced Immunotherapy
• Gene Transfer
• Others

Cancer Gene Therapy Market, By Indication:

• Breast Cancer
• Ovarian Cancer
• Lung Cancer
• Liver Cancer
• Pancreatic Cancer
• Prostate Cancer
• Others

Cancer Gene Therapy Market, By End User:

• Biotechnology & Pharmaceutical Companies
• Academic & Research Institutions
• Others

Cancer Gene Therapy Market, By Region:

• North America
  • United States
  • Mexico
  • Canada
• Europe
  • France
  • Germany
  • United Kingdom
  • Italy
  • Spain
• Asia-Pacific
  • China
  • India
  • South Korea
  • Japan
  • Australia
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Global Cancer Gene Therapy Market.

Available Customizations:

Global Cancer Gene Therapy Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Clinical Trial Analysis

• 5.1. Ongoing Clinical Trials
• 5.2. Completed Clinical Trials
• 5.3. Terminated Clinical Trials
• 5.4. Breakdown of Pipeline, By Development Phase
• 5.5. Breakdown of Pipeline, By Status
• 5.6. Breakdown of Pipeline, By Study Type
• 5.7. Breakdown of Pipeline, By Region
• 5.8. Clinical Trials Heat Map

6. Global Cancer Gene Therapy Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Therapy (Oncolytic Virotherapy, Gene Induced Immunotherapy, Gene Transfer, Others)
  • 6.2.2. By Indication (Breast Cancer, Ovarian Cancer, Lung Cancer, Liver Cancer, Pancreatic Cancer, Prostate Cancer, Others)
  • 6.2.3. By End User (Biotechnology & Pharmaceutical Companies, Academic & Research Institutions, Others)
  • 6.2.4. By Region
  • 6.2.5. By Company (2024)
• 6.3. Market Map

7. North America Cancer Gene Therapy Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Therapy
  • 7.2.2. By Indication
  • 7.2.3. By End User
  • 7.2.4. By Country
• 7.3. North America: Country Analysis
  • 7.3.1. United States Cancer Gene Therapy Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Therapy
      • 7.3.1.2.2. By Indication
      • 7.3.1.2.3. By End User
  • 7.3.2. Canada Cancer Gene Therapy Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Therapy
      • 7.3.2.2.2. By Indication
      • 7.3.2.2.3. By End User
  • 7.3.3. Mexico Cancer Gene Therapy Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Therapy
      • 7.3.3.2.2. By Indication
      • 7.3.3.2.3. By End User

8. Europe Cancer Gene Therapy Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Therapy
  • 8.2.2. By Indication
  • 8.2.3. By End User
  • 8.2.4. By Country
• 8.3. Europe: Country Analysis
  • 8.3.1. France Cancer Gene Therapy Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Therapy
      • 8.3.1.2.2. By Indication
      • 8.3.1.2.3. By End User
  • 8.3.2. Germany Cancer Gene Therapy Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Therapy
      • 8.3.2.2.2. By Indication
      • 8.3.2.2.3. By End User
  • 8.3.3. United Kingdom Cancer Gene Therapy Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Therapy
      • 8.3.3.2.2. By Indication
      • 8.3.3.2.3. By End User
  • 8.3.4. Italy Cancer Gene Therapy Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Therapy
      • 8.3.4.2.2. By Indication
      • 8.3.4.2.3. By End User
  • 8.3.5. Spain Cancer Gene Therapy Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Therapy
      • 8.3.5.2.2. By Indication
      • 8.3.5.2.3. By End User

9. Asia-Pacific Cancer Gene Therapy Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Therapy
  • 9.2.2. By Indication
  • 9.2.3. By End User
  • 9.2.4. By Country
• 9.3. Asia-Pacific: Country Analysis
  • 9.3.1. China Cancer Gene Therapy Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Therapy
      • 9.3.1.2.2. By Indication
      • 9.3.1.2.3. By End User
  • 9.3.2. India Cancer Gene Therapy Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Therapy
      • 9.3.2.2.2. By Indication
      • 9.3.2.2.3. By End User
  • 9.3.3. Japan Cancer Gene Therapy Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Therapy
      • 9.3.3.2.2. By Indication
      • 9.3.3.2.3. By End User
  • 9.3.4. South Korea Cancer Gene Therapy Market Outlook
    • 9.3.4.1. Market Size & Forecast
      • 9.3.4.1.1. By Value
    • 9.3.4.2. Market Share & Forecast
      • 9.3.4.2.1. By Therapy
      • 9.3.4.2.2. By Indication
      • 9.3.4.2.3. By End User
  • 9.3.5. Australia Cancer Gene Therapy Market Outlook
    • 9.3.5.1. Market Size & Forecast
      • 9.3.5.1.1. By Value
    • 9.3.5.2. Market Share & Forecast
      • 9.3.5.2.1. By Therapy
      • 9.3.5.2.2. By Indication
      • 9.3.5.2.3. By End User

10. South America Cancer Gene Therapy Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Therapy
  • 10.2.2. By Indication
  • 10.2.3. By End User
  • 10.2.4. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Cancer Gene Therapy Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Therapy
      • 10.3.1.2.2. By Indication
      • 10.3.1.2.3. By End User
  • 10.3.2. Argentina Cancer Gene Therapy Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Therapy
      • 10.3.2.2.2. By Indication
      • 10.3.2.2.3. By End User
  • 10.3.3. Colombia Cancer Gene Therapy Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Therapy
      • 10.3.3.2.2. By Indication
      • 10.3.3.2.3. By End User

11. Middle East and Africa Cancer Gene Therapy Market Outlook

• 11.1. Market Size & Forecast
  • 11.1.1. By Value
• 11.2. Market Share & Forecast
  • 11.2.1. By Therapy
  • 11.2.2. By Indication
  • 11.2.3. By End User
  • 11.2.4. By Country
• 11.3. MEA: Country Analysis
  • 11.3.1. South Africa Cancer Gene Therapy Market Outlook
    • 11.3.1.1. Market Size & Forecast
      • 11.3.1.1.1. By Value
    • 11.3.1.2. Market Share & Forecast
      • 11.3.1.2.1. By Therapy
      • 11.3.1.2.2. By Indication
      • 11.3.1.2.3. By End User
  • 11.3.2. Saudi Arabia Cancer Gene Therapy Market Outlook
    • 11.3.2.1. Market Size & Forecast
      • 11.3.2.1.1. By Value
    • 11.3.2.2. Market Share & Forecast
      • 11.3.2.2.1. By Therapy
      • 11.3.2.2.2. By Indication
      • 11.3.2.2.3. By End User
  • 11.3.3. UAE Cancer Gene Therapy Market Outlook
    • 11.3.3.1. Market Size & Forecast
      • 11.3.3.1.1. By Value
    • 11.3.3.2. Market Share & Forecast
      • 11.3.3.2.1. By Therapy
      • 11.3.3.2.2. By Indication
      • 11.3.3.2.3. By End User

12. Market Dynamics

• 12.1. Drivers
• 12.2. Challenges

13. Market Trends & Developments

• 13.1. Recent Developments
• 13.2. Mergers & Acquisitions
• 13.3. Product Launches

14. Competitive Landscape

• 14.1. Abeona Therapeutics Inc.
  • 14.1.1. Business Overview
  • 14.1.2. Company Snapshot
  • 14.1.3. Products & Services
  • 14.1.4. Financials (As Reported)
  • 14.1.5. Recent Developments
  • 14.1.6. Key Personnel Details
  • 14.1.7. SWOT Analysis
• 14.2. Asklepios BioPharmaceutical Inc.
• 14.3. Altor Bioscience Inc.
• 14.4. BioCancell Inc.
• 14.5. Celgene Inc.
• 14.6. Elevate Bio Inc.
• 14.7. Genelux Corporation
• 14.8. Introgen Therapeutics Inc.
• 14.9. OncoGenex Pharmaceuticals Inc.
• 14.10. Merck KGaA

15. Strategic Recommendations

16. About Us & Disclaimer